Get the Stockscreener App
8.56
1.83%
-0.16
After Hours:
8.56
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Exclusive Access: Cullinan Therapeutics Leadership Reveals Strategy at Elite Healthcare Forums - StockTitan
Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM) - SETE News
CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month LowHere's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by Analysts - MarketBeat
FY2024 Earnings Estimate for CGEM Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Forecast for CGEM FY2024 Earnings? - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings? - Defense World
Ratio Revelations: Cullinan Therapeutics Inc (CGEM)’s Financial Metrics in the Spotlight - The Dwinnex
CGEM Stock Sees Decline of Approximately -5.74% in Last Five Days - Knox Daily
Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach - Fierce Biotech
SG Americas Securities LLC Has $283,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Has Bearish Outlook for CGEM FY2025 Earnings - MarketBeat
Equities Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for CGEM - Defense World
HC Wainwright Boosts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $33.00 - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for CGEM Issued By HC Wainwright - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cullinan reports zipalertinib study met primary endpoint - MSN
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Cullinan Therapeutics Reveals Next-Gen Pipeline Details at Major Biotech Conference - StockTitan
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - Defense World
Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market - Citeline
Cullinan Management Achieves Milestone in Cancer Trial - TipRanks
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by JPMorgan Chase & Co. - Defense World
Cullinan Therapeutics Says Zipalertinib Trial Met Primary Endpoint -January 29, 2025 at 04:38 am EST - Marketscreener.com
Cullinan Reveals Update On REZILIENT1 Trial Data For Zipalertinib In Non-Small Cell Lung Cancer - RTTNews
Game-Changing Lung Cancer Drug Shows Promise: New Hope for EGFR Mutation Patients - StockTitan
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - PR Newswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Reviewing Repligen (NASDAQ:RGEN) and Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week LowHere's What Happened - MarketBeat
Harbor Capital Advisors Inc. Purchases 9,385 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Should You Sell? - MarketBeat
Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics' chief scientific officer sells shares worth $50,040 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4%What's Next? - MarketBeat
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):